Predict Smarter.
De-Risk Earlier.
Successful lead candidates are those that translate into a stable, robust, and manufacturable therapeutic. Too often, developability risks surface late, extending timelines, creating downstream bottlenecks, and causing costly failures.
This is where Genedata comes in.
Genedata tracks all biologics molecules from early discovery to development and gives the UCB R&D organization central access to all relevant information on these molecules.
Hector Sanchez
Senior Director of R&D Informatics
Working with Genedata […] provides us with fast, flexible, and reliable options to discover potential biotherapeutic liabilities and thoroughly analyze next-generation antibodies at Sanofi.
Soraya Hölper, Ph.D.,
Laboratory Head Mass Spectrometry
Developability in Action.
Genedata Webinar Week.
- Discover how teams at Boehringer Ingelheim, Ferring, and Eli Lilly accelerate developability decisions with integrated data
- Explore real-world workflows across molecule design, characterization, and CMC
- Learn how leading biopharma organizations reduce risk earlier and advance candidates with confidence
_______________________________________________________________________________________________________________________________________________________________________________________
The Best Candidates.
From the Get-Go.
- Anticipate issues earlier and prioritize the best molecules for development right from the start
- Avoid weak predictions by giving AI/ML models access to more complete, less biased datasets instead of relying on the few “successful” molecules
- Reduce unnecessary wet‑lab experiments to improve overall efficiency, throughput, and costs
From Prediction to Validation. Grounded in Assays.
- Automate the capture and analysis of key developability assay data, including SEC, DLS, DSF, CE-SDS, and SPR/BLI
- Leverage MS-based multi-attribute method (MAM) to extract multiple attributes from a single assay, enriching the developability profile with fewer runs
- Standardize methods, metadata, and calculations across experiments to ensure comparability of results across teams and locations
- Combine assay readouts into a coherent, longitudinal developability profile that supports confident decisions from early screening through development
Developability Identified.
End-to-End.
- Evaluate production suitability from drug discovery to development to promote shared understanding of risks across functions
- Advance the most promising drug candidates, guided by full context, not by isolated downstream results
- Continuously assess developability to support proactive, evidence-based decisions
Audit-ready.
Compliant by Design.
- Make evidence‑based go/no‑go decisions using complete data lineage, connecting discovery insights, analytics, and manufacturability
- Operate within a standardized, traceable, GxP‑ready environment to ensure auditability as programs move toward regulated development
- Move faster without compromising quality, reducing uncertainty early, and advancing only candidates with credible developability profiles
